Searchicon: search

Merck Animal Health to Showcase Latest Innovations in Veterinary Medicine at WSAVA 2026

October 12, 2026

Educational symposia offer the latest learnings on allergic dermatitis in dogs, parasite management, and infectious disease treatment and prevention protocols

RAHWAY, N.J., Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will host scientific symposia showcasing the latest clinical advancements in canine allergic dermatitis, parasite protection, and infectious disease prevention protocols at the 2026 World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland.
 
“Sharing our latest innovations at WSAVA reflects how MSD Animal Health continues to help drive transformative veterinary medicine for companion animals and those that care for them. We are focused on advancing companion animal health through treatment and prevention in parasite control and well-being,” said Delair Bolis, associate vice president, Global Companion Animals, MSD Animal Health. “We are proud to lead the industry with solutions that help make a meaningful difference for pets and their caregivers worldwide.”
 
At this year’s Congress, attendees are invited to visit the MSD Animal Health booth (#04) to explore the latest breakthroughs shaping veterinary medicine, including the launch of NOBIVAC® NXT Feline vaccines, the innovation of NUMELVI®, extended parasite protection with BRAVECTO® Injectable, and the 30-year milestone of the AFYA Program’s global rabies elimination mission.
 
Key Symposia at WSAVA:
Breaking the Itch Cycle: Diagnosis, Treatment, and Prevention of Allergic Dermatitis
Tuesday, October 13, 2026: 13:15-14:15
Parallel Hall 5
Presenters: Linda Horspool, BVMS, PhD, DECVPT, MRCVS; Patrick Hensel, DVM, DACVD, DECVD; Galia Sheinberg, DVM, ESP, DLACVD;  Dawid Janczak, DVM, PhD
 
This comprehensive veterinary symposium delivers an end-to-end clinical framework for tackling allergic dermatitis, guiding practitioners from initial diagnosis through long-term disease management. The program begins with a stepwise diagnostic approach to systematically rule out differentials and confirm underlying allergic conditions, followed by evidence-based multimodal strategies, including targeted anti-inflammatory therapy, rapid pruritus control, and skin barrier restoration, tailored to individual patient needs. Rounding out the sessions, the symposium emphasizes the critical role of continuous, year-round flea control in preventing and mitigating flare-ups, equipping veterinary professionals with practical, integrated solutions to optimize patient comfort and dermatologic outcomes.
 
Retrovirus Reality Check: Cracking the Code of FeLV & FIV
Wednesday, October 14, 2026: 12:45-13:45
Parallel Hall 4
Presenters: Melissa Bourgeois, DVM, PhD, DACVM; Petra Cerna, PhD, DACVIM, Dipl. ECVIM-CA, DABVP, MANZCVS
 

This clinical session delivers a comprehensive overview of feline retrovirus infections, equipping veterinary teams with actionable strategies for the diagnosis, clinical evaluation, and long-term management of feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Attendees will explore primary and confirmatory testing methodologies alongside practical approaches to managing clinical signs and associated comorbidities in infected cats. Additionally, the lecture introduces NOBIVAC NXT Feline, detailing the science behind its cutting-edge RNA particle technology and demonstrating how this next-generation vaccine can proactively advance feline preventive care and elevate standard protocol outcomes in clinical practice.

About Merck Animal Health

Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is a global animal health business committed to The Science of Healthier Animals™. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).